CooperCompanies Reports Strong Revenue Growth and Strategic Progress

Cooper Companies ( (COO) ) has released its Q4 earnings. Here is a breakdown of the information Cooper Companies presented to its investors.

CooperCompanies is a global medical device company specializing in contact lenses and fertility and women’s health products, with operations in over 130 countries. In its latest earnings report, CooperCompanies announced a 5% increase in fourth-quarter revenue to $1,065.2 million and a 5% rise in full-year revenue to $4.1 billion, with organic growth slightly lower. The company reported a decline in GAAP diluted EPS by 27% for the quarter, while non-GAAP EPS rose by 11%, indicating strong operational performance despite restructuring costs. Key highlights include CooperVision’s growth driven by MyDay contract wins and a 37% increase in MiSight sales, alongside CooperSurgical’s robust performance in the fertility sector. The company completed significant reorganization activities, resulting in improved cash flow and a positive outlook for 2026, with expectations of over $2.2 billion in free cash flow from 2026 to 2028. Looking ahead, CooperCompanies aims to accelerate growth and profitability, supported by strategic investments and share repurchases, positioning itself for sustained shareholder value.